Lineage Cell Therapeutics, Inc. Capital Expenditures Incurred but Not yet Paid
Lineage Cell Therapeutics, Inc. (LCTX) reported Capital Expenditures Incurred but Not yet Paid of $105.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Other Cash Flow Items
us-gaap:CapitalExpendituresIncurredButNotYetPaid · last filed 2026-08-06
- Lineage Cell Therapeutics, Inc. capital expenditures incurred but not yet paid for the quarter ending 2026-06-30 was $35.00K.
- Lineage Cell Therapeutics, Inc. capital expenditures incurred but not yet paid for the quarter ending 2026-03-31 was $70.00K, a 1650.00% increase year-over-year.
- Lineage Cell Therapeutics, Inc. capital expenditures incurred but not yet paid for the quarter ending 2025-09-30 was $24.00K.
- Lineage Cell Therapeutics, Inc. capital expenditures incurred but not yet paid for the quarter ending 2025-06-30 was -$3.00K, a 105.45% decline year-over-year.
- Lineage Cell Therapeutics, Inc. capital expenditures incurred but not yet paid for fiscal 2023 was $8.00K, a 71.43% decline from fiscal 2022.
- Lineage Cell Therapeutics, Inc. capital expenditures incurred but not yet paid for fiscal 2022 was $28.00K.
| Period end | Capital Expenditures Incurred but Not yet Paid 3 month | Capital Expenditures Incurred but Not yet Paid 6 month | Capital Expenditures Incurred but Not yet Paid 9 month | Capital Expenditures Incurred but Not yet Paid 12 month |
|---|---|---|---|---|
| 2026-06-30 | $35.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $105.00K 10-Q · filed 2026-08-06 | ||
| 2026-03-31 | $70.00K 10-Q · filed 2026-05-12 | |||
| 2025-09-30 | $24.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $21.00K derived: sum of 2 quarters · filed 2026-08-06 | $25.00K 10-Q · filed 2025-11-06 | |
| 2025-06-30 | -$3.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $1.00K 10-Q · filed 2026-08-06 | ||
| 2025-03-31 | $4.00K 10-Q · filed 2026-05-12 | |||
| 2024-09-30 | -$47.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $8.00K derived: sum of 2 quarters · filed 2025-11-06 | $11.00K 10-Q · filed 2025-11-06 | $11.00K derived: sum of 4 quarters · filed 2025-11-06 |
| 2024-06-30 | $55.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-12 | $58.00K 10-Q · filed 2025-08-12 | $58.00K derived: sum of 3 quarters · filed 2025-08-12 | -$27.00K derived: sum of 4 quarters · filed 2025-08-12 |
| 2024-03-31 | $3.00K 10-Q · filed 2024-05-09 | $3.00K derived: sum of 2 quarters · filed 2024-05-09 | -$82.00K derived: sum of 3 quarters · filed 2024-11-14 | -$142.00K derived: sum of 4 quarters · filed 2024-11-14 |
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-07 | -$85.00K derived: sum of 2 quarters · filed 2024-11-14 | -$145.00K derived: sum of 3 quarters · filed 2024-11-14 | $8.00K 10-K · filed 2024-03-07 |
| 2023-09-30 | -$85.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-14 | -$145.00K derived: sum of 2 quarters · filed 2024-11-14 | $8.00K 10-Q · filed 2024-11-14 | |
| 2023-06-30 | -$60.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | $93.00K 10-Q · filed 2024-08-08 | ||
| 2023-03-31 | $153.00K 10-Q · filed 2024-05-09 | |||
| 2022-12-31 | $28.00K 10-K · filed 2024-03-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aligos Therapeutics, Inc. (ALGS) | United States | $0.238B | -0.47 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| Protalix BioTherapeutics, Inc. (PLX) | $0.221B | 9.87 | |
| ANAVEX LIFE SCIENCES CORP. (AVXL) | United States | $0.218B | -18.37 |
| Alector, Inc. (ALEC) | United States | $0.213B | -1.90 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Compass Therapeutics, Inc. (CMPX) | United States | $0.204B | -5.35 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |